本帖最后由 maicon08 于 2023-4-28 15:12 编辑
0 `8 W3 e$ \0 ^' L0 W. F( r
' }' c1 _) x. N) F7 D$ c* a2 I p& k一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。" D2 r: C8 h5 O9 q+ Z: P" }
$ Y0 A1 W/ b, W! A
https://www.163.com/dy/article/I3BTTPRD053438SI.html
9 v' }. ]5 S( |, h; e
- ]2 J% a' ^8 D+ W! B. {' `( _9 ^: P; R b4 @/ a3 j- D* Z
在研疗法-免疫治疗4 s3 {* a$ Q* }. r
Developmental Therapeutics—Immunotherapy
/ Z. d* v8 ?: f. i$ T % }3 U9 v5 c0 U% k" j
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心
% P* G$ }2 y' P) g4 n: @: {
在研疗法-分子靶向药物和肿瘤生物学
# ~6 g% _' m7 M7 a m0 F. [ Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
1 G( Y% {, t% g% m1 h摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心 6 h$ U7 L* o: I+ w L1 A
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院
+ A, D7 y R0 V
胃肠道肿瘤-结直肠癌和肛门癌8 d' H. p% t* q/ x
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院
; \6 I$ ?/ w( I5 p& S- n
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
1 P G. j) E% ^2 }* q摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 9 F- v; X0 G" l+ {9 W7 N
妇科肿瘤 Gynecologic Cancer 7 `0 H2 B) P# l( Z/ W: j
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院 9 y: \+ H; B$ t& d: F+ b. W% j% q9 p
头颈肿瘤
$ j" ^: Y/ H4 D. T/ z Head and Neck Cancer
, k8 t4 k6 P! z7 `( ^! g- F摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 * O6 d. }2 h& z5 e
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
2 _' ?" A9 x# w, n
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 7 X1 r; p0 L) r
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia " {: I$ y! e- P& ^; M" D
摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
" n( M; Q: l; u. A! u) u
血液系统恶性肿瘤-浆细胞疾病
9 K9 O8 L+ I3 C3 v8 @0 D Hematologic Malignancies—Plasma Cell Dyscrasia + x8 h. j9 y8 m2 I( c& |1 {/ E: L6 H; x
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 4 S$ u( F _' N2 @) D* t% }- @( o
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤" ~3 \9 V1 w, {! {# h4 _' a4 q9 R
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers ( N- O9 h8 Z/ k8 ], b! P' P: ?% N
摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 ( o' u2 t9 L( ~5 H/ Y1 s: Z7 [! ^8 O, P
肺癌-转移性非小细胞肺癌7 |2 W6 ]1 u# [% Q. ~+ a+ M( Z4 E
Lung Cancer—Non-Small Cell Metastatic ) z; \' Q% G- s# n
摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 + M2 S7 x# Q2 l& P
" F7 |$ f# B" G" d- X
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
% J7 L0 \8 X# ]# o
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 0 L1 o8 v1 ^8 g) u a% h. b. j
黑色素瘤/皮肤癌
! |0 X4 h, X7 T) r" M0 b$ \9 a Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 , v9 U9 b* d; u8 J7 }$ o; Y5 \
快速摘要报告
2 g* W! p- L* U2 K Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
+ @ }# \6 T7 [8 L% C6 v( g8 d
临床科学研讨会: r( o# N4 D& I4 ?3 p
Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
2 a/ b' a* U+ n I- g
: X0 W4 R5 a. u8 I9 P+ Y | 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
